Latest news with #Ibex
Yahoo
21-05-2025
- Business
- Yahoo
Global AI in Diagnostics Market to Register Stunning Growth at a CAGR of ~22% by 2032
The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies creates a solid base for integrating AI into current healthcare systems, enhancing both efficiency and accuracy. Furthermore, ongoing product innovation by major global players, driven by progress in machine learning and growing regulatory backing, is accelerating the availability of AI-based diagnostic solutions. New York, USA, May 21, 2025 (GLOBE NEWSWIRE) -- Global AI in Diagnostics Market to Register Stunning Growth at a CAGR of ~22% by 2032 | DelveInsight The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies creates a solid base for integrating AI into current healthcare systems, enhancing both efficiency and accuracy. Furthermore, ongoing product innovation by major global players, driven by progress in machine learning and growing regulatory backing, is accelerating the availability of AI-based diagnostic solutions. DelveInsight's AI in Diagnostics Market Insights report provides the current and forecast market analysis, individual leading AI in diagnostics companies' market shares, challenges, AI in diagnostics market drivers, barriers, trends, and key market AI in diagnostics companies in the market. Key Takeaways from the AI in Diagnostics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in diagnostics market during the forecast period. In the component segment of the AI in diagnostics market, the software category captured a significant revenue share in 2024. Notable AI in diagnostics companies such as Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and several others are currently operating in the AI in diagnostics market. In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, introduced the latest advancements in its innovative product platform, Ibex-AI. These new features, developed in collaboration with expert pathologists worldwide who actively use the platform in routine clinical practice, highlight Ibex's ongoing commitment to creating cutting-edge diagnostic tools tailored to the needs of healthcare professionals on the frontlines of patient care. In October 2023, Lucida Medical Ltd announced that it received Class IIb CE certification for its AI-powered prostate cancer detection software, Prostate IntelligenceTM (PiTM). Leveraging advanced AI technology, PiTM analyzes MRI scans and is seamlessly integrated into the radiologist's workflow. In March 2023, Qritive launched its latest AI-driven innovation, QAi Prostate, designed specifically for prostate cancer diagnosis. Utilizing cutting-edge machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision. To read more about the latest highlights related to the AI in diagnostics market, get a snapshot of the key highlights entailed in the Global AI in Diagnostics Market Report AI in Diagnostics Overview Artificial Intelligence (AI) is revolutionizing diagnostics by enabling faster, more accurate detection of diseases through advanced data analysis and pattern recognition. AI-powered systems can analyze medical images such as X-rays, MRIs, and CT scans with high precision, often matching or exceeding the performance of human radiologists in identifying abnormalities like tumors, fractures, or infections. By processing vast amounts of data from electronic health records, lab results, and genomics, AI algorithms can also uncover hidden correlations, assist in early disease prediction, and support personalized treatment plans. Moreover, AI is streamlining workflows in diagnostic laboratories and reducing the burden on healthcare professionals. For instance, AI-driven tools can automate routine tasks such as blood sample analysis or pathology slide interpretation, allowing clinicians to focus on complex cases. In resource-constrained settings, AI has the potential to bridge the gap in healthcare access by providing decision support to less experienced practitioners. As AI continues to evolve, integrating real-time data and improving interpretability, it holds the promise of significantly enhancing diagnostic accuracy, speed, and overall patient in Diagnostics Market Insights North America is expected to dominate the overall Artificial Intelligence (AI) in Diagnostics market over the forecast period, driven by advanced healthcare infrastructure, significant investments in AI technologies, and widespread adoption of digital health solutions. The United States, in particular, leads the region due to its early adoption of cutting-edge technologies, strong presence of leading AI and healthcare companies, and supportive regulatory frameworks. The growing demand for early and accurate diagnosis, especially for chronic and complex diseases such as cancer and cardiovascular conditions, has propelled the integration of AI into diagnostic tools and platforms. Major healthcare institutions in the region are increasingly leveraging AI algorithms for imaging analysis, pathology, and predictive diagnostics, further accelerating market growth. Moreover, robust government initiatives and funding programs supporting AI research in healthcare continue to fuel innovation and development. Strategic collaborations between technology firms and medical institutions are resulting in AI solutions with improved accuracy and efficiency, contributing to enhanced patient outcomes. The presence of a tech-savvy population, favorable reimbursement policies for AI-enabled diagnostic procedures, and a well-established ecosystem of data-driven healthcare systems also contribute to North America's leading position in this domain. As AI technologies mature and gain greater clinical acceptance, the region is expected to remain at the forefront of global advancements in AI-driven diagnostics. To know more about why North America is leading the market growth in the AI in diagnostics market, get a snapshot of the AI in Diagnostics Market Outlook AI in Diagnostics Market Dynamics The AI in diagnostics market has seen significant growth due to technological advancements in machine learning (ML) and artificial intelligence (AI), allowing for the automation and enhancement of diagnostic processes. AI-powered diagnostic tools are revolutionizing areas such as imaging, pathology, and molecular diagnostics, enabling faster, more accurate results with reduced human error. This has become especially crucial in areas like cancer detection, where early identification can significantly impact treatment outcomes. AI algorithms, capable of analyzing vast datasets, can detect patterns and abnormalities in medical imaging that may be missed by the human eye, leading to earlier intervention. The market dynamics are also being influenced by the increasing demand for personalized healthcare. As healthcare systems move towards precision medicine, AI in diagnostics plays a vital role by tailoring diagnostic tests and treatments based on individual genetic profiles. This is particularly significant in oncology, where molecular diagnostics are being enhanced by AI to offer more targeted therapeutic options. With this move toward personalized diagnostics, the role of AI in predicting disease outcomes and treatment responses continues to expand, driving the need for more sophisticated diagnostic tools. Furthermore, regulatory approvals and integration with healthcare systems are key to AI's success in diagnostics. Governments and healthcare bodies are gradually developing guidelines for AI in clinical settings, which is boosting investor confidence and enabling more widespread adoption. However, challenges such as data privacy concerns, interoperability issues, and the need for large-scale validation studies still pose barriers to the full-scale integration of AI diagnostics. As a result, partnerships between AI companies and traditional diagnostic firms are becoming more common to combine the strengths of AI technologies with the reliability and credibility of established healthcare systems. The growing prevalence of chronic diseases and the increasing burden on healthcare systems globally are also driving the adoption of AI in diagnostics. AI can assist in managing large patient populations by streamlining workflows, reducing diagnostic errors, and providing healthcare professionals with better decision-making tools. The market is also seeing the emergence of AI-driven platforms that offer end-to-end diagnostic solutions, from initial patient consultation to final diagnosis, creating a more seamless healthcare experience. As AI technologies continue to mature, the market is expected to experience even greater expansion, making healthcare more accessible, efficient, and accurate. Get a sneak peek at the AI in diagnostics market dynamics @ AI in Diagnostics Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Diagnostics Market CAGR ~22% AI in Diagnostics Market Size by 2032 USD 8 Billion Key AI in Diagnostics Companies Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, among others AI in Diagnostics Market Assessment AI in Diagnostics Market Segmentation AI in Diagnostics Market Segmentation By Component: Hardware/software, and Services AI in Diagnostics Market Segmentation By Application: Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others AI in Diagnostics Market Segmentation By Technology: Machine Learning, Natural Language Processing, and Others AI in Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in diagnostics market are set to emerge as the trendsetter explore @ AI in Diagnostics Companies Table of Contents 1 AI in Diagnostics Market Report Introduction 2 AI in Diagnostics Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Diagnostics Market Key Factors Analysis 6 AI in Diagnostics Market Porter's Five Forces Analysis 7 AI in Diagnostics Market Layout 8 AI in Diagnostics Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in diagnostics market by 2032? Click to get a snapshot of the AI in Diagnostics Market Trends Related Reports AI in Cancer Diagnostics Market AI in Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in cancer diagnostics companies, including iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Sonrai Analytics, among others. Artificial Intelligence In Clinical Trials Market Artificial Intelligence In Clinical Trials Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Precision Medicine Market Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679
Yahoo
06-05-2025
- Health
- Yahoo
AI-Driven Accuracy and Efficiency in Breast Cancer Diagnosis: New Study Validates Ibex Breast Solution
Ibex Breast Study shows Ibex's AI boosts pathologists' diagnostic accuracy to 100% and shortens case review time BOSTON, May 06, 2025--(BUSINESS WIRE)--A newly published peer-reviewed article on a study conducted at The Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution developed by Ibex Medical Analytics (Ibex), significantly improves accuracy and efficiency in evaluating breast pathology cases. The findings, published in Clinical Breast Cancer, demonstrate how AI technology can assist pathologists in providing patients with quicker and more trusted diagnostic results. "This study represents a critical step forward in validating the role of AI in breast pathology," said Zaibo Li, MD, PhD, MBA, Department of Pathology at The Ohio State University Wexner Medical Center. "Our findings show that AI-powered tools can enhance diagnostic accuracy and improve workflow by reducing review times and additional testing." The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ (DCIS), atypical lobular hyperplasia (ALH) and other benign lesions. Three expert breast pathologists independently reviewed each case digitally, both with and without the support of Ibex Breast. Results demonstrated a clear benefit: when using AI, diagnostic accuracy improved from 97.1% to 100%, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified. Pathologists using AI also experienced up to 23% reduction in review time and an average 33% decrease in immunohistochemistry (IHC) test orders; these more efficient workflows increase pathologists' productivity, reduce turnaround times, and ensure patients receive their diagnosis as soon as possible. Released in 2022, Ibex Breast detects more than 50 tissue morphologies - both malignant and benign - and has been widely adopted by leading pathology labs worldwide. The AI solution was trained and validated on a large and diverse collection of breast slides from laboratories around the world utilizing different digital scanner models. A global team of senior pathologists marked and labelled tissue morphologies, to ensure the AI's accuracy and the robustness of diagnostic support provided. By accurately classifying challenging lesions and supporting real-time diagnostic decisions, Ibex Breast delivers both clinical and operational value to pathology labs under pressure. "Beyond the numbers, Ibex Breast bolsters pathologists' confidence and peace of mind, especially when navigating complex or borderline cases. What this ultimately means is that patients can receive their diagnosis sooner – and that's absolutely critical in breast cancer, where time matters both medically and emotionally," said Dr. Manuela Vecsler, VP of Clinical and Scientific Affairs at Ibex Medical Analytics.
Reuters
27-02-2025
- Business
- Reuters
Grifols expects to boost revenue and free cash flow, shares soar
BARCELONA, Feb 27 (Reuters) - Spanish drugmaker Grifols ( opens new tab said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value. Shares in Grifols soared 13% on the day following its new outlook presentation, extending early gains after the release of a strong set of 2024 results on Wednesday, while Spain's blue-chip index Ibex was down 0.8% In a presentation to investors in London, Grifols said it expects positive free cash flow - excluding the impact of costs and expenses from merger and acquisitions - to rise to 1.2 billion euros ($1.25 billion) in 2029 and to 350 million-400 million euros in 2025 after 266 million euros last year. The Barcelona-based firm, which makes human plasma-based medicines, swung from a negative free cash flow in 2023, posting better-than-expected results, according to analysts. In its presentation to investors, Grifols - whose largest market is the United States - said it expects total revenue to grow to between 7.5 billion and 7.6 billion euros in 2025 from last year's 7.2 billion euros and to hit around 10 billion in 2029. It projected a further rise to 14 billion euros by 2034. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) should grow to at least 1.875 billion euros this year and to around 2.9 billion euros in 2029 compared to 1.779 billion euros last year. Grifols lost more than 30% of its market value last year, when Gotham City Research, a short-seller fund, released multiple reports accusing Grifols of overstating earnings and understating debt, which Grifols denies. It has sued the fund. In November, an investigating magistrate at Spain's High Court opened a probe into Gotham's actions over the possible violation of market and consumer protection laws. That month, Canadian fund Brookfield dropped its plan to take over Grifols due to a disagreement over its value.
